BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24869932)

  • 1. Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis.
    Chiriaco M; Farinelli G; Capo V; Zonari E; Scaramuzza S; Di Matteo G; Sergi LS; Migliavacca M; Hernandez RJ; Bombelli F; Giorda E; Kajaste-Rudnitski A; Trono D; Grez M; Rossi P; Finocchi A; Naldini L; Gentner B; Aiuti A
    Mol Ther; 2014 Aug; 22(8):1472-1483. PubMed ID: 24869932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.
    Brendel C; Hänseler W; Wohlgensinger V; Bianchi M; Tokmak S; Chen-Wichmann L; Kuzmenko E; Cesarovic N; Nicholls F; Reichenbach J; Seger R; Grez M; Siler U
    Hum Gene Ther Methods; 2013 Jun; 24(3):151-9. PubMed ID: 23489116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.
    Santilli G; Almarza E; Brendel C; Choi U; Beilin C; Blundell MP; Haria S; Parsley KL; Kinnon C; Malech HL; Bueren JA; Grez M; Thrasher AJ
    Mol Ther; 2011 Jan; 19(1):122-32. PubMed ID: 20978475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease.
    Roesler J; Brenner S; Bukovsky AA; Whiting-Theobald N; Dull T; Kelly M; Civin CI; Malech HL
    Blood; 2002 Dec; 100(13):4381-90. PubMed ID: 12393624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease.
    Brendel C; Rothe M; Santilli G; Charrier S; Stein S; Kunkel H; Abriss D; Müller-Kuller U; Gaspar B; Modlich U; Galy A; Schambach A; Thrasher AJ; Grez M
    Hum Gene Ther Clin Dev; 2018 Jun; 29(2):69-79. PubMed ID: 29664709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD/SCID mouse xenograft.
    Naumann N; De Ravin SS; Choi U; Moayeri M; Whiting-Theobald N; Linton GF; Ikeda Y; Malech HL
    Gene Ther; 2007 Nov; 14(21):1513-24. PubMed ID: 17728796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic Tumors in a Mouse Model of X-linked Chronic Granulomatous Disease after Lentiviral Vector-Mediated Gene Therapy.
    Jofra Hernández R; Calabria A; Sanvito F; De Mattia F; Farinelli G; Scala S; Visigalli I; Carriglio N; De Simone M; Vezzoli M; Cecere F; Migliavacca M; Basso-Ricci L; Omrani M; Benedicenti F; Norata R; Rancoita PMV; Di Serio C; Albertini P; Cristofori P; Naldini L; Gentner B; Montini E; Aiuti A; Mortellaro A
    Mol Ther; 2021 Jan; 29(1):86-102. PubMed ID: 33010230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.
    Kaufmann KB; Brendel C; Suerth JD; Mueller-Kuller U; Chen-Wichmann L; Schwäble J; Pahujani S; Kunkel H; Schambach A; Baum C; Grez M
    Mol Ther; 2013 Mar; 21(3):648-61. PubMed ID: 23207695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lentiviral Gene Therapy of Chronic Granulomatous Disease: Functional Assessment of Universal and Tissue-Specific Promoters.
    Yuan H; Wu X; Liu H; Chang LJ
    Hum Gene Ther; 2023 Jan; 34(1-2):19-29. PubMed ID: 36274229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease.
    Stein S; Scholz S; Schwäble J; Sadat MA; Modlich U; Schultze-Strasser S; Diaz M; Chen-Wichmann L; Müller-Kuller U; Brendel C; Fronza R; Kaufmann KB; Naundorf S; Pech NK; Travers JB; Matute JD; Presson RG; Sandusky GE; Kunkel H; Rudolf E; Dillmann A; von Kalle C; Kühlcke K; Baum C; Schambach A; Dinauer MC; Schmidt M; Grez M
    Hum Gene Ther Clin Dev; 2013 Jun; 24(2):86-98. PubMed ID: 23845071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient retroviral transduction of human bone marrow progenitor and long-term culture-initiating cells: partial reconstitution of cells from patients with X-linked chronic granulomatous disease by gp91-phox expression.
    Porter CD; Parkar MH; Collins MK; Levinsky RJ; Kinnon C
    Blood; 1996 May; 87(9):3722-30. PubMed ID: 8611697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells.
    Becker S; Wasser S; Hauses M; Hossle JP; Ott MG; Dinauer MC; Ganser A; Hoelzer D; Seger R; Grez M
    Hum Gene Ther; 1998 Jul; 9(11):1561-70. PubMed ID: 9694155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy of chronic granulomatous disease.
    Grez M; Becker S; Saulnier S; Knöss H; Ott MG; Maurer A; Dinauer MC; Hoelzer D; Seger R; Hossle JP
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S99-104. PubMed ID: 10933200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level reconstitution of respiratory burst activity in a human X-linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral-mediated gene transfer of human gp91phox.
    Ding C; Kume A; Björgvinsdóttir H; Hawley RG; Pech N; Dinauer MC
    Blood; 1996 Sep; 88(5):1834-40. PubMed ID: 8781441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
    Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
    J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lentiviral Vector Gene Therapy Protects XCGD Mice From Acute Staphylococcus aureus Pneumonia and Inflammatory Response.
    Farinelli G; Jofra Hernandez R; Rossi A; Ranucci S; Sanvito F; Migliavacca M; Brombin C; Pramov A; Di Serio C; Bovolenta C; Gentner B; Bragonzi A; Aiuti A
    Mol Ther; 2016 Oct; 24(10):1873-1880. PubMed ID: 27456061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease.
    Dinauer MC; Li LL; Björgvinsdóttir H; Ding C; Pech N
    Blood; 1999 Aug; 94(3):914-22. PubMed ID: 10419882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting.
    Zou J; Sweeney CL; Chou BK; Choi U; Pan J; Wang H; Dowey SN; Cheng L; Malech HL
    Blood; 2011 May; 117(21):5561-72. PubMed ID: 21411759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gene therapy for inherited diseases using heamatopoietic stem cells--gene therapy for patients with chronic granulomatous disease].
    Nunoi H; Ishibashi F
    Hum Cell; 1999 Sep; 12(3):103-8. PubMed ID: 10695016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease.
    Barde I; Laurenti E; Verp S; Wiznerowicz M; Offner S; Viornery A; Galy A; Trumpp A; Trono D
    Gene Ther; 2011 Nov; 18(11):1087-97. PubMed ID: 21544095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.